Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. One of the products under development, SAGE-718, is based on the NMDA receptor program.
The above chart shows the details of the product under development for the NMDA Receptor program.
Overall, there are three types of ionotropic glutamate receptors:
- NMDA (or N-methyl-D-aspartate) receptor
- AMPA (or alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor
- kainic acid receptor
Sage Therapeutics has developed SAGE 718, a product that targets the NMDA Receptor. SAGE-718 is the first compound to be developed by Sage Therapeutics outside the GABA receptor program.
SAGE-718 is an oxysterol-based positive allosteric modulator of the NMDA receptor. The drug SAGE-718 is under Phase I clinical trials that are evaluating the drug as a treatment of cerebro-sterol deficit disorders, anti-NMDA receptor encephalitis, and other indications that involve NMDA receptor hypofunction.
SAGE-718 was developed as a once-daily dosage compound. The phase I single ascending dose (or SAD) trial is a double-blind placebo-controlled study to evaluate the safety, tolerance, and pharmacokinetics as well as pharmacodynamics effects of SAGE-718 when administered orally to adults once a day. The results of this trial are expected in the second half of 2017.
To divest the company-specific risks, investors can consider ETFs like the PowerShares DWA Healthcare Momentum ETF (PTH), which holds 1.4% of its total assets in Sage Therapeutics (SAGE). PTH also holds 3.5% in UnitedHealth Group (UNH), 3.2% in Becton Dickinson (BDX), and 2.6% in Aetna (AET).